Ethanesulfonic acid nintedanib dispersible tablet and preparation method thereof

A technology of nintedanib ethanesulfonate and dispersible tablets, which is applied in the directions of non-active ingredients medical preparations, active ingredients-containing medical preparations, pharmaceutical formulas, etc. High utilization effect

Inactive Publication Date: 2016-09-28
FOSHAN TENGRUI MEDICINE TECH CO LTD
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is currently no preventive method or internationally recognized curative treatment other than lung transplantation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ethanesulfonic acid nintedanib dispersible tablet and preparation method thereof
  • Ethanesulfonic acid nintedanib dispersible tablet and preparation method thereof
  • Ethanesulfonic acid nintedanib dispersible tablet and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment l

[0018] prescription:

[0019]

[0020] Preparation:

[0021] (1) Nintedanib ethanesulfonate powder (200 mesh) and sucrose powder (150 mesh) were uniformly mixed in equal increments to obtain mixture A;

[0022] (2) Pass the remaining auxiliary materials through a 200-mesh sieve, and mix them uniformly in equal increments to obtain mixture B;

[0023] (3) Mix mixture A and mixture B uniformly according to the method of equal increase, and then directly compress into tablets.

Embodiment 2

[0025] prescription:

[0026]

[0027] Preparation:

[0028] (1) Nintedanib ethanesulfonate powder (200 mesh) and lactose powder (150 mesh) were uniformly mixed in equal increments to obtain mixture A;

[0029] (2) Pass the remaining auxiliary materials through a 200-mesh sieve, and mix them uniformly in equal increments to obtain mixture B;

[0030] (3) Mix mixture A and mixture B uniformly according to the method of equal increase, and then directly compress into tablets.

Embodiment 3

[0032] prescription:

[0033]

[0034] Preparation:

[0035] (1) Nintedanib ethanesulfonate powder (200 mesh) and lactose powder (150 mesh) were uniformly mixed in equal increments to obtain mixture A;

[0036] (2) Pass the remaining auxiliary materials through a 200-mesh sieve, and mix them uniformly in equal increments to obtain mixture B;

[0037] (3) Mix mixture A and mixture B uniformly according to the method of equal increase, and then directly compress into tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an ethanesulfonic acid nintedanib dispersible tablet used for treating idiopathic pulmonary fibrosis (IPF). Ethanesulfonic acid nintedanib serves as the raw material, auxiliary materials are added, and the ethanesulfonic acid nintedanib dispersible tablet is prepared. The ethanesulfonic acid nintedanib dispersible tablet is rapid to disintegrate and absorb, high in bioavailability, convenient to take, less in intestinal tract residue, few in side effect and sweet in taste and has fragrance, medicine taking compliance of patients is particularly easy to improve, the taste of the preparation is improved, the sticking phenomenon cannot occur in the tabletting process, and industrial production is promoted.

Description

technical field [0001] The invention relates to a new dosage form of nintedanib ethanesulfonate, in particular to nintedanib ethanesulfonate dispersible tablets and a preparation method thereof. Background technique [0002] Nintedanib (Nintedanib) is an oral triple angiokinase inhibitor developed by Boehringer Ingelheim. In October 2014, FDA approved OFEV® (nintedanib) for the treatment of idiopathic pulmonary fibrosis (IPF) , becoming the first tyrosine kinase inhibitor (TKI) approved for the treatment of IPF. Nintedanib (Nintedanib) acts on growth factor receptors that have been shown to have potential effects in the pathological mechanism of pulmonary fibrosis, the most important of which are platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR). By blocking these signal transduction pathways involved in the process of fibrosis, nintedanib can slow down the progression of IPF by...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/20A61K31/496A61K47/26A61K47/38A61K47/32A61K47/20A61P11/00A61P35/00
CPCA61K9/2059A61K9/2027A61K9/2054A61K31/496
Inventor 王雪峰韩亮
Owner FOSHAN TENGRUI MEDICINE TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap